Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 million) in potential paydays from a licensing deal with Sanofi. The French ...

Formation Bio is inking a deal worth more than $600 million in biobucks for ex-China rights to a next-gen immunology asset from Lynk Pharmaceuticals. Lynk’s program will be developed by Formation’s ...

Former Pfizer, BenevolentAI, Incyte, and AMAG executives join to strengthen clinical, technology, financial, and scientific leadership as company scales its AI-native pharma model Together, these ...

PHOENIX — Dallas developer Formation Interests this week purchased an office complex near the Metrocenter redevelopment in north Phoenix, according to a news release. As part of the purchase, ...

NEW YORK, Dec. 10, 2025 /PRNewswire/ -- Formation Bio and Lynk Pharmaceuticals today announced Formation Bio's acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation ...